Fiduciary Family Office LLC Sells 2,005 Shares of IQVIA Holdings Inc. $IQV

Key Points

• Fiduciary Family Office LLC reduced its holdings in IQVIA Holdings by 36.7%, selling 2,005 shares and now owning a total of 3,451 shares valued at approximately $544,000.
• In Q2, several institutional investors increased their stakes in IQVIA, with notable increases from Mather Group LLC (up 83.5%) and Raleigh Capital Management Inc. (up 85.5%).
• IQVIA reported a 12.5% increase in quarterly earnings per share, totaling $2.81, which exceeded analysts' expectations, along with a revenue of $4.02 billion.

Fiduciary Family Office LLC reduced its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 36.7% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,451 shares of the medical research company's stock after selling 2,005 shares during the quarter. Fiduciary Family Office LLC's holdings in IQVIA were worth $544,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Mather Group LLC. grew its holdings in shares of IQVIA by 83.5% in the 1st quarter. Mather Group LLC. now owns 769 shares of the medical research company's stock valued at $136,000 after acquiring an additional 350 shares in the last quarter. Patton Fund Management Inc. acquired a new stake in shares of IQVIA in the 2nd quarter valued at approximately $231,000. Verdence Capital Advisors LLC bought a new stake in IQVIA during the second quarter worth $3,612,000. Private Advisor Group LLC lifted its stake in IQVIA by 11.6% in the first quarter. Private Advisor Group LLC now owns 5,435 shares of the medical research company's stock valued at $958,000 after acquiring an additional 566 shares during the last quarter. Finally, Raleigh Capital Management Inc. grew its position in shares of IQVIA by 85.5% in the 2nd quarter. Raleigh Capital Management Inc. now owns 3,350 shares of the medical research company's stock valued at $528,000 after acquiring an additional 1,544 shares during the period. Institutional investors and hedge funds own 89.62% of the company's stock.

Insider Transactions at IQVIA

In related news, insider Keriann Cherofsky sold 549 shares of IQVIA stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the transaction, the insider owned 2,910 shares of the company's stock, valued at $557,352.30. This trade represents a 15.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Eric Sherbet sold 5,800 shares of the company's stock in a transaction on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the sale, the insider directly owned 27,178 shares in the company, valued at $5,165,178.90. This trade represents a 17.59% decrease in their position. The disclosure for this sale can be found here. Insiders own 1.60% of the company's stock.

IQVIA Trading Up 3.8%

NYSE IQV opened at $212.30 on Tuesday. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45. The company has a market cap of $36.09 billion, a price-to-earnings ratio of 30.72, a price-to-earnings-growth ratio of 2.25 and a beta of 1.32. IQVIA Holdings Inc. has a twelve month low of $134.65 and a twelve month high of $235.32. The business's fifty day moving average is $192.05 and its 200 day moving average is $169.60.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.04. The company had revenue of $4.02 billion during the quarter, compared to the consensus estimate of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The firm's revenue was up 5.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.64 earnings per share. As a group, sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

IQV has been the topic of a number of recent analyst reports. Hsbc Global Res raised IQVIA from a "hold" rating to a "strong-buy" rating in a research report on Thursday, October 9th. Weiss Ratings reaffirmed a "hold (c)" rating on shares of IQVIA in a report on Wednesday, October 8th. HSBC upgraded shares of IQVIA from a "hold" rating to a "buy" rating and upped their price target for the company from $195.00 to $235.00 in a research note on Thursday, October 9th. Barclays increased their target price on shares of IQVIA from $185.00 to $200.00 and gave the stock an "equal weight" rating in a research report on Thursday, October 2nd. Finally, Cowen reiterated a "buy" rating on shares of IQVIA in a research note on Wednesday, July 23rd. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $234.57.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.